1

			u	Comm Inited States I	issioner for Patents, Box P Patent and Trademark Off Washington, D.C. 202	
U.S. APPLICATION NO.		FIRST NAMED APPLICANT		ATTY, DOCKET NO.		
09/830810	00/920940)1925US1	
			INTERNA	ATIONAL APPLI	CATION NO.	
MELISSA D SCHWALLER			PC	CT/US99/2	5209	
FULBRIGHT & JAWORSKI 1301 MCKINNEY SUITE 51	na					
HOUSTON, TX 77010 3095	50		I.A. FILING D.		PRIORITY DATE	
			28 OCT	99	28 OCT 98	
1			DATE MA	пер: 3 (MAY 2001	
NOTIFICATION OF M	HSSING REQUESTION	UIREMENTS UNDER TED/ELECTED OFFI	35 U.S.C. 3'	71 IN TE		
1. The following items have been					mark	
Office as a Designate	d Office (37 CFR	1.494) an Elected Office	(37 CFR 1.495)	i:	шагк	
U.S. Basic National	onal Fee. Indication of Small Entity Status.					
Oath or Declaration Copy of Article 19 a		Translation of Article 1 Other: IB 331, ISA/210,				
Priority Document.	menaments.	STATEMENT/SE	QUENCE LISTING	341,		
		ion Report in English and its				
Translation of Annex	es to the Internatio	nal Preliminary Examination	Report into Engl	ish.		
2. Applicant has requested earthe indicated items in paragraph 3 prior to 20 or 30 months from the U.S. Basic National	below. The Basic priority date to ave	National Fee and the copy of	f the international	ing indicate I application	ed items and/or n must be filed	
	application into En	the period set forth below in or glish. A processing fee will be months from the priority date	be required if sub		ments for	
The current tran Translation.	slation is defective	for the reasons indicated on lation of the application and/o	the attached Notice			
appropriate 20 c	or 30 months from a of the inventors, i	the priority date (37 CFR 1.4 n compliance with 37 CFR 1	92(f)). .497(a) and (b), p	properly ide	entifying	
		nternational application numb tted later than the appropriate				
indicated on the	attached PCT/DO/	s not comply with 37 CFR 1. EO/917. eclaration later than the appro-	,, ,,			
priority date (37	CFR 1.492(e)).					
4. Additional claim fees of \$	must submit the a	large entity small entity, i dditional claim fees or cancel				
5. Applicant has not submitted PCT/DO/EO/920.	the required seque	nce listing pursuant to 37 CF	R 1.821-1.825.	See attache	rd .	
ALL OF THE ITEMS SET FOR MONTHS FROM THE DATE O THE PRIORITY DATE FOR TO RESPOND WILL RESULT IN A	F THIS NOTICE TE APPLICATIO	OR BY 22 OR 32 MONTH N, WHICHEVER IS LATE	S (where 37 CF	R 1.495 ap	plies) FROM	
The time period set above may be 1.136(a).	extended by filing	a petition and fee for extension	on of time under t	he provisio	ns of 37 CFR	
6. If box 3a or 3c is checked, a tr Annexes will be cancelled. A prov 7. The Article 19 amendments or 30 (37 CFR 1.495(d)) months for	essing fee will be a are cancelled since	required if submitted later tha a translation was not provide	n 20 or 30 month	ns from the	priority date.	
Applicant is reminded that any con address given in the heading and in				ıst be maile	d to the	
Enclosed: PCT/DO/EO/917	☐ Notic	IUST be returned will e of Defective Translation	th this respo	onse.		
PTO-875	E PC17	DO/EO/920 Christin	e S. Washing	ton		
FORM PCT/DO/EO/905 (March 2	001)	Telephone:	703-305-3752			

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

			www	
U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/830810	MATZUK	М	P01925US1	
		INTERNATIONAL A	APPLICATION NO.	
MELISSA D SCHWALLER FULBRIGHT & JAWORSKI		PCT/US9	CT/US99/25209	
1301 MCKINNEY SUITE 5100 HOUSTON, TX 77010 3095		1.A. FILING DATE	PRIORITY DATE	
10031011, 1277010 3093		28 OCT 99	28 OCT 98	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
🕱 A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements o 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d). The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
PPLICANT MUST PROVIDE: X An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
amendment directing its entry into the specification.
A statement that the contents of the paper or compact disc and the computer readable form
are the same and, where applicable, include no new matter, as required by 37 CFR
1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
OR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE ALL:
(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.
Christine S. Washington

Telephone: 703-305-3752

FORM PCT/DO/EO/920 (March 2001)